Investor Presentation Q1-Q3 2020
78
Investor presentation
First nine months of 2020
International Operations at a glance.
Novo NordiskⓇ
Million
Diabetes trend
700
DKK
billion
22%
200
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
First nine months
2020
Sales
Growth²
(MDKK)
80%
Long-acting insulin³
7,590
14%
600
I
26%
I
Premix insulin4
7,799
8%
GLP-1
150
60%
Fast-acting insulin5
8,170
8%
500
29%¹
Human insulin
5,872
8%
I
400
Insulin
Total insulin
29,431
10%
100
40%
300
637
GLP-16
8,087
37%
4%1
522
Other Diabetes care?
2,250
(12%)
200
415
50
20%
Diabetes care
39,768
13%
100
9%1
OAD
Obesity care
1,611
8%
(SaxendaⓇ)
0
2019
2030
Population with diabetes
O Diabetes growth rate
0
Aug
2045
2015
0%
Diabetes & Obesity
41,379
12%
Aug
2020
care
Biopharm³
9,020
8%
GLP-1 MS Insulin MS
-OAD MS
Total
50,399
12%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas 9th Edition 2019
1 CAGR calculated for 5-year period; Competitor insulin value market
shares, as of Aug 2020: Novo Nordisk 49%, Sanofi 29% and Eli Lilly 15%;
Competitor GLP-1 value market shares, as of Aug 2020: Novo Nordisk
52%, Eli Lilly 43% and AstraZeneca 5%; OAD: Oral anti-diabetic; MS:
Market share; Source: IQVIA MAT, Aug 2020 value figures
2 At Constant exchange rates; 3 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ: 4
Comprises RyzodegⓇ and NovoMix®; 5 Comprises FiaspⓇ and NovoRapidⓇ;
Comprises VictozaⓇ and Ozempic®; 7 Comprises Novo Norm® and needles; 8
Comprises primarily NovoSeven®, Novo Eight® NovoThirteen®, Refixia®,
Norditropin, Vagifem® and ActivelleⓇ
6View entire presentation